2,861 matches for your search in the start-up spotlight
rss
BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company's award-winning TRIC ...
A new star is born, a new light in the sky of bioanalytics: Accelerō® Bioanalytics. Inspired by expert knowledge. Old hands at work. We are committed to become a preferred partner in bioanalytical services for the nucleic acids biotechnology and pharmaceutical industry. Accelerō® Bioanalytics ...
Spindiag is a spin-off of Hahn-Schickard, one of the world's leading research institutions for microsystems technology. Based on its patented microfluidic platform "LabDisk", Spindiag develops an easy-to-use, compact, and automated point-of-care system for the broad, fast, and affordable ...
The object of the company is the development and marketing of the TolerogenixX process in various severe and most severe indications. It is a cell therapy procedure, innovation and unique selling point is the specific suppression of the immune reaction in the sense of an individualized ...
We are a company focused on the research, development and manufacturing of innovative diagnostic tests to determine risk factors of dementia-related diseases. We have set ourselves the goal of being able to diagnose the various forms of dementia earlier and more reliably through the innovative ...
Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor ...
t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction ...
CYPRUMED® is a biopharmaceutical company developing a next generation platform technology for the oral delivery of polypeptides. The patent pending technology is entirely based on GRAS listed compounds and easy to formulate. In vivo studies with various polypeptide drugs in rodents, dogs and none ...
